Jorge F. DiMartino M.D., Ph.D.
Net Worth
Last updated:
What is Jorge F. DiMartino M.D., Ph.D. net worth?
The estimated net worth of Mr. Jorge F. DiMartino M.D., Ph.D. is at least $3,647,886 as of 4 Jan 2024. He owns shares worth $277,416 as insider, has earned $310,030 from insider trading and has received compensation worth at least $3,060,440 in Kronos Bio, Inc..
What is the salary of Jorge F. DiMartino M.D., Ph.D.?
Mr. Jorge F. DiMartino M.D., Ph.D. salary is $765,110 per year as Chief Medical Officer & Executive Vice President of Clinical Devel. in Kronos Bio, Inc..
How old is Jorge F. DiMartino M.D., Ph.D.?
Mr. Jorge F. DiMartino M.D., Ph.D. is 62 years old, born in 1963.
What stocks does Jorge F. DiMartino M.D., Ph.D. currently own?
As insider, Mr. Jorge F. DiMartino M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Kronos Bio, Inc. (KRON) | Chief Medical Officer & Executive Vice President of Clinical Devel. | 315,246 | $0.88 | $277,416 |
What does Kronos Bio, Inc. do?
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Jorge F. DiMartino M.D., Ph.D. insider trading
Kronos Bio, Inc.
Mr. Jorge F. DiMartino M.D., Ph.D. has made 7 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 12,009 units of KRON stock worth $14,219 on 4 Jan 2024.
The largest trade he's ever made was exercising 18,657 units of KRON stock on 12 Dec 2022. As of 4 Jan 2024 he still owns at least 315,246 units of KRON stock.
Kronos Bio key executives
Kronos Bio, Inc. executives and other stock owners filed with the SEC:
- Dr. Norbert W. Bischofberger Ph.D. (69) Pres, Chief Executive Officer & Director
- Dr. Yasir B. Al-Wakeel BCh, BM, MA (43) Chief Financial Officer & Head of Corporation Devel.
- Mr. David M. Tanen J.D. (54) Sec. & Director
- Mr. Jorge F. DiMartino M.D., Ph.D. (62) Chief Medical Officer & Executive Vice President of Clinical Devel.
- Mr. Joshua A. Kazam (48) Co-Founder & Director